Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method

Journal of Virological Methods

Volumn 185, Issue 1, 2012, Pages 94-100

  Besse, Bernard ^a   Coste Burel, Marianne ^a   Bourgeois, Nathalie ^a   Feray, Cyrille ^a   Imbert Marcille, Berthe Marie ^a   André Garnier, Elisabeth ^a  

^a HÔTEL DIEU   (France)

Author keywords

HCV; NS3 protease sequencing; Protease inhibitors; Resistance mutations

Indexed keywords

NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; VIRUS RNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; BOOTSTRAPPING; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; NS3 GENE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UNINDEXED SEQUENCE; VALIDATION PROCESS; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYLOGENY; PROTEASE INHIBITORS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84864303595     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.06.011     Document Type: Article

References (37)

1. Bartels D.J., Zhou Y., Zhang E.Z., Marcial M., Byrn R.A., Pfeiffer T., Tigges A.M., Adiwijaya B.S., Lin C., Kwong A.D., Kieffer T.L. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. The Journal of Infectious Diseases 2008, 198:800-807.
2. Curry S., Qiu P., Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. Journal of Virological Methods 2008, 153:156-162.
3. Delaugerre C., Flandre P., Chaix M.L., Ghosn J., Raffi F., Dellamonica P., Jaeger H., Shürmann D., Cohen-Codar I., Van P.N., Norton M., Taburet A.-M., Delfraissy J.-F., Rouzioux C. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrobial Agents Chemotherapy 2009, 53:2934-2939.
4. Fonseca-Coronado S., Escobar-Gutiérrez A., Ruiz-Tovar K., Cruz-Rivera M.Y., Rivera-Osorio P., Vazquez-Pichardo M., Carpio-Pedroza J.C., Ruíz-Pacheco J.A., Cazares F., Vaughan G. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. Journal of Clinical Microbiology 2012, 50:281-287.
5. Franco S., Bellido R., Aparicio E., Cañete N., García-Retortillo M., Solà R., Tural C., Clotet B., Paredes R., Martínez M.A. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. Journal of Viral Hepatitis 2011, 18:e578-e582.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002, 347:975-982.
7. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. Journal of Hepatology 2011, 55:192-206.
8. Imhof I., Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011, 53:1090-1099.
9. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364:2405-2416.
10. Kieffer T.L., Kwong A.D., Picchio G.R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). The Journal of Antimicrobial Chemotherapy 2010, 65:202-212.
11. Kim A.Y., Timm J., Nolan B.E., Reyor L.L., Kane K., Berical A.C., Zachary K.C., Lauer G.M., Kuntzen T., Allen T.M. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. Journal of Infectious Disease 2009, 199:737-741.
12. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., Lee B., Heckerman D., Carlson J., Reyor L.L., Kleyman M., McMahon C.M., Birch C., Schulze Zur Wiesch J., Ledlie T., Koehrsen M., Kodira C., Roberts A.D., Lauer G.M., Rosen H.R., Bihl F., Cerny A., Spengler U., Liu Z., Kim A.Y., Xing Y., Schneidewind A., Madey M.A., Fleckenstein J.F., Park V.M., Galagan J.E., Nusbaum C., Walker B.D., Lake-Bakaar G.V., Daar E.S., Jacobson I.M., Gomperts E.D., Edlin B.R., Donfield S.M., Chung R.T., Talal A.H., Marion T., Birren B.W., Henn M.R., Allen T.M. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008, 48:1769-1778.
13. Kwong A.D., McNair L., Jacobson I., George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Current Opinion in Pharmacology 2008, 8:522-531.
14. Lange C.M., Sarrazin C., Zeuzem S. Specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Alimentary Pharmacology and Therapeutics 2010, 32:14-28.
15. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
16. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., McNair L., Alam J., Muir A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. The New England Journal of Medicine 2009, 360:1827-1838.
17. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H., Heathcote E.J., Zeuzem S., Reesink H.W., Garg J., Bsharat M., George S., Kauffman R.S., Adda N., Di Bisceglie A.M. Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine 2010, 362:1292-1303.
18. Monpoeho S., Maul A., Bonnin C., Patria L., Ranarijaona S., Billaudel S., Ferré V. Clearance of human-pathogenic viruses from sludge: study of four stabilization processes by real-time reverse transcription-PCR and cell culture. Applied and Environmental Microbiology 2004, 70:5434-5440.
19. Nasu A., Marusawa H., Ueda Y., Nishijima N., Takahashi K., Osaki Y., Yamashita Y., Inokuma T., Tamada T., Fujiwara T., Sato F., Shimizu K., Chiba T. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE 2011, 6:e24907.
20. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Current Topics in Microbiology and Immunology 2006, 299:261-284.
21. Pawlotsky J.-M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
22. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.-P. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1195-1206.
23. Recordon-Pinson P., Soulié C., Flandre P., Descamps D., Lazrek M., Charpentier C., Montes B., Trabaud M.-A., Cottalorda J., Schneider V., Morand-Joubert L., Tamalet C., Desbois D., Macé M., Ferré V., Vabret A., Ruffault A., Pallier C., Raymond S., Izopet J., Reynes J., Marcelin A.-G., Masquelier B. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrobial Agents Chemotherapy 2010, 54:3335-3340.
24. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Molecular Biology Evolution 1987, 4:406-425.
25. Sandres-Sauné K., Deny P., Pasquier C., Thibaut V., Duverlie G., Izopet J. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. Journal of Virological Methods 2003, 109:187-193.
26. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Zhou Y., Chu H.-M., Lin C., Weegink C., Reesink H., Zeuzem S., Kwong A.D. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
27. Shaw T., Bartholomeusz A., Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. Journal of Hepatology 2006, 44:593-606.
28. Shindo H., Maekawa S., Komase K., Sueki R., Miura M., Kadokura M., Shindo K., Amemiya F., Kitamura T., Nakayama Y., Inoue T., Sakamoto M., Okada S.-I., Asahina Y., Izumi N., Honda M., Kaneko S., Enomoto N. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatology International 2011.
29. Soriano V., Peters M.G., Zeuzem S. New therapies for hepatitis C virus infection. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America 2009, 48:313-320.
30. Susser S., Vermehren J., Forestier N., Welker M.W., Grigorian N., Füller C., Perner D., Zeuzem S., Sarrazin C. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology 2011.
31. Susser S., Welsch C., Wang Y., Zettler M., Domingues F.S., Karey U., Hughes E., Ralston R., Tong X., Herrmann E., Zeuzem S., Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
32. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular Biology and Evolution 2011, 28:2731-2739.
33. Treviño A., de Mendoza C., Parra P., Rodríguez C., Madejón A., Plaza Z., del Romero J., Poveda E., Soriano V. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antiviral Therapy (London) 2011, 16:413-416.
34. Trimoulet P., Belzunce C., Faure M., Wittkop L., Reigadas S., Dupon M., Ragnaud J.-M., Fleury H., Neau D. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Medicine 2011, 12:506-509.
35. Vallet S., Viron F., Henquell C., Le Guillou-Guillemette H., Lagathu G., Abravanel F., Trimoulet P., Soussan P., Schvoerer E., Rosenberg A., Gouriou S., Colson P., Izopet J., Payan C. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antiviral Therapy 2011, 16:1093-1102.
36. Vermehren J., Susser S., Lange C.M., Forestier N., Karey U., Hughes E., Ralston R., Tong X., Zeuzem S., Sarrazin C. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. Journal of Viral Hepatitis 2012, 19:120-127.
37. Welsch C., Domingues F.S., Susser S., Antes I., Hartmann C., Mayr G., Schlicker A., Sarrazin C., Albrecht M., Zeuzem S., Lengauer T. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology 2008, 9:R16.